Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Dr Mike Gosselin Selected to Lead Aprecia′s Product Development Team

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Dr Mike Gosselin will serve as Vice President of Pharmaceutical Development and will oversee product development from early innovation to commercial production at Aprecia’s 3DP Center of Excellence in Blue Ash, Ohio.

“Aprecia will continue to grow at a rapid pace by licensing our novel 3DP formulation platforms to enable the development and enhance the value of partnered products,” said Chris Gilmore, Aprecia’s Chief Executive Officer. “We continue to add accomplished scientists to realize our mission to deliver unique products through global partnerships. I am pleased to welcome Mike into this important leadership role to ensure that we exceed the expectations for our product development programs.”

“Aprecia’s 3D-Printing technology platforms enable the next level of creative freedom and manufacturing agility to help product formulators break through the constraints of conventional pharmaceutical manufacturing technologies,” Gosselin stated. “I am honored to join the industry leaders in 3DP at Aprecia, and I look forward to collaborating with our clients to design novel dosage forms, accelerate time to market, and reduce the cost of product development.”

Gosselin is an experienced executive with 20 years managing people and projects in pharmaceutical development and manufacturing operations. He is well experienced in dosage formulation and process development, scale-up, validation, and manufacturing for solid oral, liquid, and liquid-fill capsule products.

About Aprecia Pharmaceuticals, LLC
Founded in 2003, Aprecia received the first and only FDA approved three-dimensionally-printed (3DP) prescription pharmaceutical product approval. This breakthrough achievement opened the door to the FDA for the entire industry. Aprecia’s ZipDose® Technology creates rapidly disintegrating oral dosage forms that are easy to take and easy to administer including engineered and coated particles for low or high dose products (over a 1000mg). Aprecia directly owns a patent estate for novel 3DP equipment and pharmaceutical 3DP applications. It licenses its exclusive technology platform as a specialty CDMO to pharmaceutical partners to extend product lines, to improve patient reach and experience, and to help address FDA requirements for pediatric delivery forms.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine